News
Primary surgery for advanced ovarian cancer significantly improves progression-free survival but not overall survival ...
1d
MedPage Today on MSNPrimary Surgery for Ovarian Cancer Scores a Win -- Sort OfPrespecified subgroup analyses showed that primary surgery conferred greater benefits for patients with stage III disease and ...
2d
MedPage Today on MSNWin for Added Relacorilant in Platinum-Resistant Ovarian CancerIn addition, mirvetuximab soravtansine (Elahere) was the first targeted therapy to demonstrate an improvement in OS in ...
Researchers compare relacorilant plus nab-paclitaxel with nab-paclitaxel monotherapy in patients with platinum-resistant ...
CBS Boston on MSN1h
A warning about an earlier outbreak of the Norovirus and a new way to detect ovarian cancerRep. Madeleine Dean's Banana Burn Against Commerce Secretary Howard Lutnick Goes Viral ...
Ovarian cancer isn't silent - learn the early warning signs. Persistent bloating, pelvic pain, urinary symptoms revealed.
Michele Hoaglund, who bought the store about a decade ago from its founding owners, was diagnosed with ovarian cancer around ...
2d
GlobalData on MSNASCO25: Imunon shares positive results from trial of IMNN-001 for ovarian cancerUS-based biotechnology company Imunon has reported positive results from its Phase II OVATION 2 trial of IMNN-001 for ovarian ...
Adding relacorilant to nab-paclitaxel improved survival outcomes in patients with platinum-resistant ovarian cancer.
ASCO 2025: Corcept Therapeutics’ relacorilant emerges as promising agent in recurrent ovarian cancer
Relacorilant blocks GR activation, a key pathway driving stress-induced chemoresistance in ovarian cancer cells.
Here is a recap of every FDA approval announced by the regulatory agency in the month of May, spanning various cancer types.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results